CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $4.03M, lower than 95% of all stocks globally
- PositionOperating margin is -5917.5%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
565.33MUSDvs all stocks (USD)
Revenue (TTM)
4.03MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.27xvs all stocks
52-Week Change
-31.51%vs all stocks
Market Capitalization
565.33MUSDvs all stocks (USD)
Enterprise Value
560.60MUSDvs all stocks (USD)
Forward P/E
-3.74xvs Biotechnology peers
Price to Book (MRQ)
7.41xvs Biotechnology peers
Enterprise to Revenue
138.97xvs Biotechnology peers
Enterprise to EBITDA
-2.81xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-41.46%vs Biotechnology peers
Return on Equity (TTM)
-216.06%vs Biotechnology peers
Revenue (TTM)
4.03MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0250USDUpdated Jul 19, 2026Quarterly Revenue Growth
-41.10%vs Biotechnology peers
Gross Profit (TTM)
-150.14MUSDvs all stocks (USD)
EBITDA (TTM)
-199.14MUSDvs all stocks (USD)
Net Income (TTM)
-198.37MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-41.13%vs Biotechnology peers
Operating Cash Flow (TTM)
-156.42MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-78.32MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.63MUSDFY2025 · Dec 31, 2025Operating Income
-208.35MUSDvs all stocks (USD)
Pre-tax Income
-201.14MUSDFY2025 · Dec 31, 2025Net Income
-201.14MUSDFY2025 · Dec 31, 2025EBIT
-208.35MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-201.46MUSDFY2025 · Dec 31, 2025Research & Development
160.64MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
52.35MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.15MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-201.14MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-163.58MUSDFY2025 · Dec 31, 2025Free Cash Flow
-168.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
76.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-201.14MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
7.32MUSDFY2025 · Dec 31, 2025Stock-based Compensation
29.27MUSDFY2025 · Dec 31, 2025Other Non-cash Items
9.70MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
996.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.72MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.53MUSDFY2025 · Dec 31, 2025Purchase of Investments
-205.41MUSDFY2025 · Dec 31, 2025Sale of Investments
101.18MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-108.76MUSDFY2025 · Dec 31, 2025Other Financing Charges
12.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
150.39MUSDFY2025 · Dec 31, 2025Shares Outstanding
180.62MSharesUpdated Jul 19, 2026Float Shares
114.96MSharesUpdated Jul 19, 2026Shares Short
34.73MSharesUpdated Jul 19, 2026Short Ratio
10.33daysvs all stocks
Short % of Shares Outstanding
24.61%vs all stocks
% Held by Insiders
23.76%vs all stocks
% Held by Institutions
66.65%vs all stocks
Total Cash (MRQ)
135.50MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7500USDUpdated Jul 19, 2026Total Debt (MRQ)
114.51MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.49xvs Biotechnology peers
Current Ratio (MRQ)
3.80xvs Biotechnology peers
Book Value per Share (MRQ)
0.4250USDUpdated Jul 19, 2026Total Assets
342.73MUSDvs all stocks (USD)
Total Current Assets
181.29MUSDFY2025 · Dec 31, 2025Total Liabilities
221.87MUSDFY2025 · Dec 31, 2025Total Non-current Assets
161.44MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
184.42MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
63.03MUSDFY2025 · Dec 31, 2025Other Short-term Investments
114.65MUSDFY2025 · Dec 31, 2025Accounts Payable
8.89MUSDFY2025 · Dec 31, 2025Short-term Debt
8.14MUSDFY2025 · Dec 31, 2025Deferred Revenue
7.82MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.70MUSDFY2025 · Dec 31, 2025Long-term Debt
108.29MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-888.35MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
120.87MUSDvs all stocks (USD)
52-Week Low
2.67USDUpdated Jul 19, 202652-Week High
6.94USDUpdated Jul 19, 202652-Week Change
-31.51%vs all stocks
Beta
2.27xvs all stocks
50-Day MA
3.30USDUpdated Jul 19, 2026200-Day MA
3.88USDUpdated Jul 19, 2026Avg 10-Day Volume
4.53MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.87MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.23USDUpdated Jul 19, 2026Other Income / Expense
3.06MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -5917.5%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -59.18Industry median: -0.34Industry P5: -43.55Peers compared: 261
Return on equity is -216.1%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -2.16Industry median: -0.22Industry P5: -1.66Peers compared: 261
Debt-to-equity is 1.49×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 1.49Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.80Altman Z-Score: -3.59
Financial Health
Altman Z-Score -3.59: distress zoneCritical
Altman Z-Score: -3.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $4.03M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,034,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Sunflower Great Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Kanghui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Zeria Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Longda Meishi Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated